THURSDAY, Jan. 23, 2025 (HealthDay News) -- Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback